Working Group Blume - Biomedical technology and Regenerative medicine
The working group of Prof. Blume is part of the Excellence Program “Biofabrication for Nife”, sponsored by the County of Lower Saxony, Germany. It is dedicated to the “Biotesting” of materials and substances for their application as elements of intelligent implants for patients. In detail, a number of cell biological tests and viability assays have been established to evaluate the biocompatibility of these materials and substances using human cells. The testing is performed on a scientific level and does not support a clinical certification in first line. It comprises viability tests such as the MTT-test or the cell-titer-blue-test, morphological tests (screening necrosis: Calcein-staining – alternatively: REM, for apoptosis: Caspase 3,7-test), tests for senescence (the ß-galactosidase-test), tests for toxicity (the MTT and the LDH-test-alternatively the LDH and BCA-test combined), tests for proliferation (the BrdU-test for determination of the IC 50% as a standard), tests for DNA damage (the Comet-test). Whereas murine cell lines are used for prescreening, for the main testing human cell lines such as Hep2G2 or A549 are used. Also the secretom of the tested cells depending on the used materials can be investigated. In addition to DNA-arrays for transcriptomics also a method for proteomics is established (Magapix Biorad). Depending on the quality and application form of the tested materials, experimental approaches will be adapted or further developed. A further cell target are human adipogenous mesenchymal stem cells, which are very suitable for biotesting either in a 2-D or in a 3-D approach.
In the field of medicine technology, the main focus is on the development of technical prerequisites for cell cultivating in tissue engineering. A relevant part for successful tissue cultivation is the selection, conditioning and regulation of suitable bioreactors. In detail, we develop a suitable bioreactor for a bioartificial vascular graft for implantation into patients with atherosclerotic complications. Here new sensor techniques and possibilities for a touchless monitoring for quality control of the cultivated graft are developed. The reactor shall offer conditions that simulate the physiological factors within the fetal circulation during vasculogenesis. For that purpose and as part of regenerative medicine, cell biological basics concerning the differentiation of human mesenchymal stem cells out of different cell sources (fatty tissue, bone marrow) are explored and further developed.
Many projects are performed together with clinical groups from the MHH and with industry partners.